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Abstract. A series of tellurides was evaluated as carbonic anhydrase (CA, EC 4.2.1.1) inhibitors against 
the human (h) carbonic anhydrase isoforms hCA I, II, IV, VII and IX, involved in a variety of diseases, 
including glaucoma, retinitis pigmentosa, epilepsy, arthritis and tumors. These compounds, which are 
the first tellurium-containing derivatives acting as inhibitors of carbonic anhydrase enzymes, showed 
effective inhibition against all isoforms investigated and some of them were selective for inhibiting the 
cytosolic or the membrane-bound CAs. Thus, these carbonic anhydrase inhibitors are interesting leads 
for the development of isoform-selective inhibitors. 
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1. Introduction
Tellurium is a rare element and, unlike the other group VI members (e.g., O, S, and Se), which have many 
biological applications, this element has not any known such function.1During the last decades, inorganic 
tellurium derivatives were employed for the development of innovative materials, such as fluorescent 
CdTe quantum dots as probes in biological detection,2,3 telluride clusters, nanoparticles and nanotubes, 
which found potential applications in the electronics and medicine fields.4-6 At the same time, a range of 
organotellurium compounds were developed, being shown that they possess a range of unique properties 
such as interesting activity against pathogenic microorganisms,7,8 inhibition of cancer cells growth,9-11 
potent caspase and cathepsin inhibitory propieties12 and antioxidant activity, which are often superior to 
those of the selenium analogues.13,14 In this particular context, we should mention carbonic anhydrase 
(CAs, EC 4.2.1.1) an enzyme that plays an important role in many physiological and pathological 
processes associated with pH control, ion transport, fluid secretion and biosynthetic reactions.19-21 Recent 
studies from our group15 reported that some of the many CA isoforms known to date, more precisely, the 
human (h) isoform hCA VII, was involved in the oxidative stress defence processes, interfering with the 
generation of reactive oxygen species (ROS).16–17 Furthermore, isoform hCA IX, which is overexpressed 
in a wide range of hypoxic tumors, where it participates to the survival, proliferation, and metastasis 
processes, was recently investigated by our groups for its interaction with selenium-containing CA 
inhibitors (CAIs).18 For these reasons we decided to also investigate various Te(II) derivatives as human 
(h) CA inhibitors (CAIs).
2. Results and discussion
2.1. Chemistry 
Our long dated interest in the study of chalcogen-containing compounds22 led us to disclose synthetic 
routes towards organoselenides23 and, more recently, organotellurides24 through the ring opening of 
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strained heterocycles with selenium and tellurium nucleophilic species. Some of these novel organic 
chalcogenides exhibited interesting antioxidant properties.25 With the aim to evaluate the CA inhibitor 
activity of a series of Te-containing compounds, a wide variety of functionalized dialkyl and aryl-alkyl 
tellurides has thus been obtained following the Scheme 1. Dialkyl substituted β -hydroxy- and β -amino- 
tellurides 4 and 5 were synthesised by treating Li2Te with epoxides 1 and aziridines 3, respectively. 
Through the same route, dithiatellurepane 6 was achieved from thiirane 2. β -Phenyltelluro thiol 7 and the 
corresponding disulfide 8 were selectively obtained from thiirane 2 and diphenyl ditelluride. Reaction of 
PhTe-, generated through reduction of PhTeTePh, with epoxides and aziridines led smoothly to the 










































Scheme 1: Synthesis of -functionalized tellurides. Li2Te is generated in situ from elemental Te (0.5 eq.) 
and LiEt3BH (1.0 eq.). PhTe- is generated in situ from PhTeTePh (0.5 eq.) and NaBH4 (1.5 eq.).
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Following a similar synthetic approach, novel chiral N-Tosyl β -aryltelluro amines were synthesised from 
diaryl ditellurides and enantioenriched aziridines, obtained from natural aminoacids, through a high 

















Scheme 2: Synthesis of -aryltelluro amines. Reagent and conditions: a) ArTeTeAr (0.5 eq.) , NaBH4 (1.5 
eq.), EtOH, 0°C.






























































Chart 1: Tellurium-containing chemotypes investigated as CA inhibitors in this work
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2.2. Carbonic anhydrase inhibition
All compounds 4a-12b were tested in vitro for their inhibitory activity against the physiologically relevant 
hCA isoforms I, II, IV, VII and IX by means of the stopped-flow carbon dioxide hydration assay26 and 
their activities were compared to the standard CAI acetazolamide (AAZ) (Table 1).
Table 1. Inhibition data of human CA isoforms I, II, IV, VII and IX with compounds 4a-12b and AAZ 
by a stopped flow CO2 hydrase assay.26
KI (μM)*
Cmp hCA I hCA II hCA IV hCA VII hCA IX
4a >100 >100 >100 >100 >100
4b >100 >100 >100 >100 >100
4c >100 >100 >100 >100 >100
5a 0.71 0.03 60.8 0.62 3.4
5b 18.0 0.09 >100 5.3 19.7
6 >100 >100 >100 >100 >100
7 >100 >100 >100 >100 >100
8 >100 >100 >100 >100 >100
9a >100 >100 >100 >100 >100
9b >100 >100 >100 >100 >100
10a 27.3 35.8 85.8 3.2 1.5
10b >100 56.8 >100 4.8 11.0
10c 76.5 61.6 >100 0.05 >100
11a >100 41.6 >100 5.0 0.7
11b >100 31.4 >100 3.2 2.0
12a >100 56.3 >100 4.1 2.3
12b >100 56.1 >100 4.9 11.7
AAZ 0.25 0.012 0.074 0.006 0.025
* Mean from 3 different assays, by a stopped flow technique (errors were in the range of  5-10 % of the 
reported values).
We have investigated a range of telluride and ditelluride derivatives for their interaction with the five hCA 
here considered, after a period of 15 min of incubation of the enzyme and inhibitor solutions26–28. The 
following structure activity relationship (SAR) may be noted regarding the inhibition data of Table 1:
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Cytosolic isoforms (hCA I, hCA II and hCA VII) were inhibited by isopropyl substituted amino 
telluride 5a in nanomolar range with particulary efficacy against hCA II (Ki 0.03 μM). Indeed, 
membrane isoforms here considered was inhibited by 5a in low micromolar range for 
transmembrane hCA IX (Ki 3.4 μM) and medium micromolar range for hCA IV (Ki 60.4 μM). 
The inhibition potency decreased when isopropyl moiety was replaced with methyl group (5b). 
On the other hand, the isopropyl moiety increased the selectivity versus hCA II with an activity 
200 folds greater than against hCA I and nearly 60 times greater thans against hCA VII. 
Furthermore, this substitution caused a loss of activity for membrane isoform hCA IV. 
Dithiatellurepane 6, β hydroxy tellurides (4a-c), β phenyltelluro substituted thiol 7, disulfide 8 
and alcohols 9a-b did not inhibit the human isoforms here considered. β phenyl telluro amine 
10a showed a good selectivity for hCA IX. This compound was 20 times more potent than two 
dominant cytosolic isoforms (hCA I hCA II) and 2 folds more active compared to hCA VII. 
An interesting inhibition profile was observed for compounds 11a and 12a, where the 
introduction of para substituents in the aryl telluro scaffolds led to a loss of activity for hCA I 
and hCA IV. Moreover, for compound 11a, CH3 group in position 4 of the aryl telluride, 
increased 7 times the selectivity for hCA IX compared to hCA VII. The benzyl moiety in 
compounds 10b and 12b moved the selectivity for hCA VII and caused a loss of inhibitory 
power against hCA I and hCA IV. Another interesting point, was the inhibitory activity of 10c. 
Methyl moiety increased over 1000 folds the selectivity for hCA VII among the other cytosolic 




We have investigated a serie of tellurides as inhibitors on five α-carbonic anhydrases (CAs, EC 4.2.1.1) 
of pharmacologic relevance, i.e., hCA I, II, IV, VII and IX. These isoforms are drug targets for 
antiglaucoma (hCA I, II and IV), antiepileptic (hCA VII) or antitumor (hCA IX) agents. In this contest, 
the investigated organotellurium compounds showed inhibitory action and in same case selectivity 
against the cytosolic over membrane-bound isoforms for compounds 5a-b and 10c. On the other hand, 
compounds 10a, 11a-b and 12a showed selectivity against the membrane tumor-associated hCA IX over 
cytosolic isoforms. In the future, it will be interesting to test organotellurium compounds as anti-
infectives against key enzymes that are expressed by pathogenic bacteria, such as the β- and γ-carbonic 
anhydrases from Burkholderia pseudomallei29 and Francisella tularensis30 the etiological agents of 
meliodosis and tularemia, respectively.
4. Experimental Part
4.1. General
All reactions were carried out in an oven-dried glassware under inert atmosphere (N2). All commercial 
materials were used as received without further purification. Flash column chromatography purifications 
were performed on Silica gel 60 (230-400 mesh). Thin layer chromatography was performed on TLC 
plates Silica gel 60 F254. NMR spectra were recorded in CDCl3 with Varian Gemini 200, Mercury 400, 
and Bruker 400 Ultrashield spectrometers operating at 200 and 400 MHz (for 1H), 50 and 100 MHz (for 
13C), and 126 MHz (for 125Te). NMR signals were referenced to nondeuterated residual solvent signals 
(7.26 ppm for 1H, 77.0 ppm for 13C). (PhTe)2 was used as an external reference for 125Te NMR (δ= 420 
ppm). 1H NMR data are reported as follows: chemical shift, integration, multiplicity (s = singlet, d = 
doublet, ap d = apparent doublet, m = multiplet, dd = doublet of doublet, ecc.), coupling constant (J) or 
line separation (ls), and assignment.
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4.1.1 General procedure for the synthesis of -hydroxy tellurides (4), -amino tellurides (5) and 
dithiatellurepane (6).
A suspension of Li2Te in THF, generated from elemental tellurium (0.5 mmol, 1.0 eq.) and LiEt3BH 
(1.0mmol, 2.0 eq.), was treated with the electrophile (epoxide, aziridine or thiirane - 1.0 mmol, 2.0 eq.) 
and the reaction was stirred for 12 h at ambient temperature. Afterwards, the mixture was diluted with 
Et2O (10 mL), filtered through a short plug of celite, washed with NH4Cl and then with H2O (2x 5 mL). 
The organic phase was dried over Na2SO4, filtered and evaporated under reduced pressure. The crude 
residue was then purified by flash chromatography to yield β-functionalised tellurides.
4.1.2 Procedure for the synthesis of β -phenyltelluro thiol (7) 
NaBH4 (28 mg, 0.75 mmol, 3.0 eq.) was portionwise added to a solution of diphenyl ditelluride (102 mg, 
0.25 mmol, 1.0 eq.) in EtOH (2 mL) at 0 °C under inert atmosphere (N2). After 30 min, the thiirane 2 (0.5 
mmol, 2.0 eq.) was slowly added and the reaction mixture was stirred at 0 °C and the reaction progress 
was monitored by TLC. When the starting thiirane had completely reacted (monitored by TLC), 2 mL of 
a 50% aqueous solution of citric acid were added and the organic phase was extracted with Et2O (2 x 5 
mL), washed with brine (1 x 5 mL), dried over Na2SO4, filtered and concentrated under vacuum. The 
crude material was purified by flash chromatography to yield β -phenyltelluro thiol 7. 
4.1.3 Procedure for the synthesis of β -phenyltelluro disulfide (8)
PhTe−, generated as described for the synthesis of thiol 7, was reacted with thiirane 2 at 0 °C and the 
reaction mixture was allowed to warm to ambient temperature before leaving to react 14 h at the same 
temperature. Then, 2 mL of H2O were added and the organic phase was extracted with Et2O (2 x 5 mL), 
washed with brine (1 x 5 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The 
crude material was purified by flash chromatography to yield β -phenyltellurodisulfides 8.
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4.1.4 General Procedure for the synthesis of -phenyltelluro alcohols (9) and N-Ts protected -
aryltelluro amines (10-12).
NaBH4 (28 mg, 0.75 mmol, 3.0 eq.) was portionwise added to a solution of diaryl ditelluride (0.25 mmol, 
1.0 eq.) in EtOH (2 mL) at 0°C under inert atmosphere (N2). After 30 min, the electrophile (epoxide or 
aziridine - 0.45 mmol, 1.8 eq.) was slowly added and the reaction mixture was stirred at room temperature 
until complete consumption of the starting material was observed by TLC. The reaction was quenched by 
addition of saturated aq. NH4Cl (2 mL) and diluted with Et2O (5 mL). The layers were separated and the 
organic layer was washed with H2O (3 mL), dried over Na2SO4, filtered and concentrated under vacuum. 
The crude material was purified by flash chromatography to yield β -phenyltelluro alcohols (9) or β -
aryltelluro amines (10-12).
4.1.5 (S)-4-methyl-N-(3-methyl-1-(phenyltellanyl)butan-2-yl)benzenesulfonamide (10a) 
Following the general procedure, diphenyl ditelluride (51 mg, 0.125 mmol) and (S)-2-isopropyl-1-
tosylaziridine (54 mg, 0.23 mmol) gave after flash chromatography (petroleum ether/Et2O 7:1) 10a (80 
mg, 78%). 1H NMR (400 MHz, CDCl3) δ(ppm): 0.74 (3H, d, J=6.7 Hz), 0.80 (3H, d, J=6.8 Hz), 1.78-
1.90 (1H, m), 2.38 (3H, s, CH3), 2.72 (1H, dd, J=6.5, 12.1 Hz, CHaHbTe), 3.10 (1H, dd, J=4.6, 12.1 Hz, 
CHaHbTe), 3.18-3.20 (1H, m, CHNH), 4.75 ( 1H, d, J=8.8 Hz, NH), 7.17-7.20 (4H, m), 7.29-7.33 (1H, 
m), 7.61-7.63 (4H, m). 13C NMR (100 MHz, CDCl3) δ(ppm): 14.6 (CH2Te), 17.5, 19.2, 32.3, 59.3, 110.9 
(TeC), 127.0, 128.0, 129.3, 129.6, 137.8, 138.8, 143.2. MS (ESI positive) m/z (%): 468 [M+Na]+, (100). 




Following the general procedure, diphenyl ditelluride (51 mg, 0.125 mmol) and (S)-2-benzyl-1-
tosylaziridine (65 mg, 0.23 mmol) gave after flash chromatography (petroleum ether/Et2O 3:1) 10b (105 
mg, 93%). 1H NMR (400 MHz, CDCl3) δ(ppm): 2.38 (3H, s, CH3), 2.74 (1H, dd, J=6.8, 13.8 Hz), 2.84-
2.89 (2H, m), 3.12 (1H, dd, J=4.3, 12.4 Hz), 3.51-3.59 (1H, m, CHNH), 4.78 (1H, d, J=7.5 Hz, NH), 6.90-
6.92 (2H, m), 7.10-7.22 (7H, m), 7.29-7.33 (1H, m), 7.45 (2H, ap d, ls=8.3 Hz), 7.65-7.67 (2H, m). 13C 
NMR (100 MHz, CDCl3) δ(ppm): 16.1 (CH2Te), 21.5, 42.0, 55.3, 111.1 (TeC), 126.7, 127.0, 128.0, 128.6, 
129.2, 129.4, 129.5, 136.5, 137.0, 138.6, 143.1. 125Te NMR (126 MHz, CDCl3) δ(ppm) : 386.4. MS (ESI 
positive) m/z (%): 516 [M+Na]+, (100). Elemental analysis: C23H23NO2STe Calcd. C 53.59%, H 4.70%, 
N 2.84%. Found: C 53.47%, H 4.73%, N 2.86%.
4.1.7 (S)-4-methyl-N-(1-(phenyltellanyl)propan-2-yl)benzenesulfonamide (10c)
Following the general procedure, diphenyl ditelluride (51 mg, 0.125 mmol) and (S)-2-methyl-1-
tosylaziridine (47 mg, 0.23 mmol) gave after flash chromatography (petroleum ether/Et2O 2:1) 10c (78 
mg, 81%). 1H NMR (400 MHz, CDCl3) δ(ppm): 1.16 (3H, d, J=6.5 Hz), 2.43 (3H, s, CH3), 2.87 (1H, dd, 
J=6.6, 12.4 Hz, CHaHbTe), 3.06 (1H, dd, J=4.7, 12.4 Hz, CHaHbTe), 3.48-3.71 (1H, m, CHNH), 4.69 
(1H, d, J=7.7 Hz, NH), 7.18-7.34 (5H, m), 7.64-7.69 (4H, m). 13C NMR (100 MHz, CDCl3) δ(ppm): 18.6 
(CH2Te), 21.5, 22.9, 50.1, 111.0 (TeC), 127.0, 128.0, 128.8, 129.4, 129.7, 138.6, 143.4. MS (ESI positive) 
m/z (%): 440 [M+Na]+, (100). Elemental analysis: C16H19NO2STe Calcd. C 46.09%, H 4.59%, N 3.36%. 
Found: C 46.16%, H 4.56%, N 3.35%.
4.1.8 (S)-4-methyl-N-(3-methyl-1-(p-tolyltellanyl)butan-2-yl)benzenesulfonamide (11a)
Following the general procedure, 1,2-di-p-tolylditellane (55 mg, 0.125 mmol) and (S)-2-isopropyl-1-
tosylaziridine (54 mg, 0.23 mmol) gave after flash chromatography (petroleum ether/EtOAc 5:1) 11a (76 
mg, 72%). 1H NMR (400 MHz, CDCl3) δ(ppm): 0.74 (3H, d, J=6.7 Hz, CH3), 0.8 (3H, d, J=6.8 Hz, CH3), 
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1.8-1.9 (1H, m), 2.36 (3H, s, CH3), 2.39 (3H, s, CH3), 2.66 (1H, dd, J=6.6, 12.2 Hz, CHaHbTe), 3.05 (1H, 
dd, J=4.6, 12.2 Hz, CHaHbTe), 3.11-3.17 (1H, m, CHNH), 4.75 (1H, d, J=8.9 Hz, NH), 7.0 (2H, ap d, 
ls=7.9 Hz), 7.17 (2H, ap d, ls=8 Hz), 7.52 (2H, ap d, ls=7.9 Hz), 7.62 (2H, ap d, ls=8 Hz). 13C NMR (100 
MHz, CDCl3) δ(ppm): 14.5 (CH2Te), 17.5, 19.2, 21.2, 21.5, 32.3, 59.3, 106.7 (TeC), 127.0, 129.5, 130.2, 
137.8, 138.1, 139.2, 143.1. MS (ESI positive) m/z (%): 482 [M+Na]+, (100). Elemental analysis: 
C19H25NO2STe Calcd. C 49.71%, H 5.49%, N 3.05%. Found: C 49.65%, H 5.51%, N 3.06%.
4.1.9 (S)-4-methyl-N-(1-phenyl-3-(p-tolyltellanyl)propan-2-yl)benzenesulfonamide (11b)
Following the general procedure, 1,2-di-p-tolylditellane (55 mg, 0.125 mmol) and (S)-2-benzyl-1-
tosylaziridine (65 mg, 0.23 mmol) gave after flash chromatography (petroleum ether/EtOAc 5:1) 11b (101 
mg, 87%). 1H NMR (400 MHz, CDCl3) δ(ppm): 2.36 (3H, s, CH3), 2.39 (3H, s, CH3), 2.74 (1H, dd, J=6.8, 
13.8 Hz), 2.79-2.88 (3H, m), 3.08 (1H, dd, J=4.3, 12.4 Hz), 3.47-3.57 (1H, m, CHNH), 4.72 (1H, d, J=7.5 
Hz, NH), 6.90-6.92 (2H, m), 7.02 (2H, d, ls=8.0 Hz), 7.11 (2H, d, ls=8.3 Hz), 7.12-7.17 (3H, m), 7.44 
(2H, d, ls=8.3 Hz), 7.56 (2H, d, ls=8.0 Hz). 13C NMR (100 MHz, CDCl3) δ(ppm): 16.2 (CH2Te), 21.2, 
21.5, 41.7, 55.3, 106.9 (TeC), 126.7, 127.0, 128.6, 129.2, 129.5, 130.3, 136.6, 137.0, 138.1, 139.0, 143.1. 
125Te NMR (126 MHz, CDCl3) δ(ppm): 371.3. MS (ESI positive) m/z (%): 530 [M+Na]+, (100). Elemental 
analysis: C23H25NO2STe Calcd. C 54.48%, H 4.97%, N 2.76%. Found: C 54.52%, H 4.95%, N 2.75%.
4.1.10 (S)-N-(1-((4-methoxyphenyl)tellanyl)-3-methylbutan-2-yl)-4-methylbenzenesulfonamide 
(12a)
Following the general procedure, 1,2-bis(4-methoxyphenyl)ditellane (59 mg, 0.125 mmol) and (S)-2-
isopropyl-1-tosylaziridine (54 mg, 0.23 mmol) gave after flash chromatography (petroleum ether/EtOAc 
5:1) 12a (81 mg, 74%). 1H NMR (400 MHz, CDCl3) δ(ppm): 0.73 (3H, d, J=6.7 Hz), 0.79 (3H, d, J=6.8 
Hz), 1.81-1.89 (1H, m), 2.39 (3H, s, CH3), 2.63 (1H, dd, J=6.7, 12.2 Hz, CHaHbTe), 3.02 (1H, dd, J=4.6, 
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12.2 Hz, CHaHbTe), 3.1-3.15 (1H, m, CHNH), 3.81 (3H, s, OCH3), 4.72 (1H, d, J=8.9 Hz, NH), 6.74 (2H, 
d, ls=8.7 Hz), 7.18 (2H, d, ls=8 Hz), 7.57 (2H, d, ls=8.7 Hz), 7.61 (2H, d, ls=8 Hz). 13C NMR (100 MHz, 
CDCl3) δ(ppm): 14.8 (CH2Te), 17.5, 19.2, 21.5, 32.2, 55.2, 59.4, 99.8 (TeC), 115.3, 127.0, 129.5, 137.9, 
141.3, 149.1. 125Te NMR (126 MHz, CDCl3) δ(ppm): 363.27. MS (ESI positive) m/z (%): 498 [M+Na]+, 




Following the general procedure, 1,2-bis(4-methoxyphenyl)ditellane (30 mg, 0.063 mmol) and (S)-2-
benzyl-1-tosylaziridine (32 mg, 0.113 mmol) gave after flash chromatography (petroleum ether/EtOAc 
5:1) 12b (54 mg, 91%). 1H NMR (400 MHz, CDCl3) δ(ppm): 2.39 (3H, s, CH3); 2.74-2.76 (2H, m); 2.79 
(1H, dd, J=6.5, 13.8 Hz); 3.05 (1H, dd, J=4.3, 12.4 Hz); 3.47-3.55 (1H, m, CHNH); 3.82 (3H, s, OCH3); 
4.75 (1H, d, J=8 Hz, NH); 6.76 (2H, ap.d, ls=8.8 Hz); 6.79-6.91 (2H, m); 7.11-7.17 (5H, m); 7.43 (2H, d, 
ls=8.3 Hz); 7.62 (2H, ap.d, ls=8.8 Hz). 13C NMR (100 MHz, CDCl3) δ(ppm): 16.4 (CH2Te); 21.5; 41.8; 
55.18; 55.23; 100.0 (TeC); 115.4; 126.7; 127.0; 128.6; 129.2; 129.5; 136.6; 137.0; 141.1; 143.1. 125Te 
NMR (126 MHz, CDCl3) δ(ppm): 369.51. MS (ESI positive) m/z (%): 546 [M+Na]+, (100). Elemental 
analysis: C23H25NO3STe Calcd. C 52.81%, H 4.82%, N 2.68%. Found: C 52.75%, H 4.84%, N 2.69%.
4.2. Carbonic anhydrase inhibition
An Applied Photophysics stopped-flow instrument has been used for assaying the CA catalyzed CO2 
hydration activity.26 Phenol red (at a concentration of 0.2 mM) has been used as indicator, working at the 
absorbance maximum of 557 nm, with 20 mMHepes (pH 7.5) as buffer, and 20 mM Na2SO4 (for 
maintaining constant the ionic strength), following the initial rates of the CA-catalyzed CO2 hydration 
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reaction for a period of 10–100 s. The CO2 concentrations ranged from 1.7 to 17 mM for the determination 
of the kinetic parameters and inhibition constants. For each inhibitor at least six traces of the initial 5–
10% of the reaction have been used for determining the initial velocity. The uncatalyzed rates were 
determined in the same manner and subtracted from the total observed rates. Stock solutions of inhibitor 
(0.1 mM) were prepared in distilled-deionized water and dilutions up to 0.01 nM were done thereafter 
with the assay buffer. Inhibitor and enzyme solutions were preincubated together for 15 min at room 
temperature prior to assay, in order to allow for the formation of the E-I complex. The inhibition constants 
were obtained by non-linear least-squares methods using PRISM 3 and the Cheng–Prusoff equation, as 
reported earlier,27,28 and represent the mean from at least three different determinations. All CA isofoms 
were recombinant ones obtained in-house as reported earlier.27,28
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